Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jonathan Friedberg
With
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Each of the following criteria must be met in order for a patient to be considered eligible for registration:
Biopsy proven (with hematopathology review at one of the participating sites to confirm correct histology in accordance with World Health Organization) indolent lymphoma to include the following diagnoses:
* Grade 1, 2, or 3a follicular lymphoma
* Small lymphocytic lymphoma (CLL excluded)
* Marginal zone lymphoma (nodal or splenic)
* Mucosal-associated lymphoid tissue
Measurable disease defined by Lugano criteria
No prior anti-lymphoma systemic therapy; prior radiation therapy allowed
Age 18 or over
Ann Arbor stages II, III or IV
Patients with follicular lymphoma must have PET FDG-avid lymphoma and fulfill Low tumor burden by Groupe D'Etude des Lymphomes Folliculaires (GELF) criteria:
* No mass \> 7 cm
* \< 3 distinct masses of greater than 3 cm
* No B symptoms
* No splenomegaly \> 16 cm by computed tomography (CT) scan
* No risk of vital organ compression
* No leukemic phase \> 5000/µl circulating lymphocytes (except for in patients with splenic marginal zone diagnosis)
* No cytopenias (platelets \< 100,000/µl, hemoglobin \< 10 g/dl, or absolute neutrophil count \< 1500/µl)
You may not be if
The following criteria will prevent inclusion of an inappropriate subject into the trial:
Osteoporosis requiring prescription treatment
Known symptomatic primary hyperparathyroidism
Hypercalcemia defined as above the institutional normal range (corrected for albumin when albumin levels are below normal)
History of calcium-related kidney stones
Creatinine \> 1.5X above upper limit of normal
Women who are known to be pregnant or who plan to become pregnant while on rituximab treatment
Clareo Health | A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma
